Drug Profile
Research programme: vaccines - Cytos Biotechnology
Alternative Names: C5aQb; CCR5Qb; CYT015-M2AP; CYT017-IL17Qb; DENAP; IL17Qb; IL1aQb; IL5Qb; IL6Qb; MIFQbLatest Information Update: 13 May 2014
Price :
$50
*
At a glance
- Originator Cytos Biotechnology
- Class Virus-like particle vaccines
- Mechanism of Action Cytokine modulators; Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Inflammation; Multiple sclerosis; Psoriasis
- No development reported Dengue; HIV infections
- Discontinued Atherosclerosis; Cancer; Creutzfeldt-Jakob disease; Hepatitis B; Hypersensitivity; Osteoporosis; Systemic lupus erythematosus
Most Recent Events
- 13 May 2014 Research programme: vaccines - Cytos Biotechnology is available for licensing as of 05 May 2014. http://www.cytos.com
- 18 Aug 2011 Suspended - Preclinical for Inflammation in Switzerland (unspecified route)
- 18 Aug 2011 Suspended - Preclinical for Multiple sclerosis in Switzerland (unspecified route)